There are currently 107 clinical trials in Fullerton, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Retina Consultants of Orange County, Neurology Center of North Orange County, Saint Jude Medical Center and Providence Medical Foundation. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
NCT05397639
Recruiting
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
08/13/2024
Locations: Neurology Center of North Orange County, Fullerton, California
Conditions: Agitation, Alzheimer's Type Dementia
Register for Updates
Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision
NCT06107881
Recruiting
One goal of this research is to conduct a non-inferiority trial of telerehabilitation versus in-office care to provide follow-up training to individuals with low vision to enhance their quality of life by using magnification devices and/or visual assistive mobile apps for important daily activities, such as reading and/or other valued tasks. This is a high priority given the increasing prevalence of low vision, paucity of low vision rehabilitation providers, and barriers related to access to car... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Southern Califonia College of Optometry, Fullerton, California
Conditions: Low Vision, Low Vision Aids
Register for Updates
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
NCT05271292
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Providence/St. Joe Cancer Institute/Crosson Cancer Institute, Fullerton, California
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Saint Jude Medical Center, Fullerton, California
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Retina Consultants of Orange County, Fullerton, California
Conditions: Age-Related Macular Degeneration
Register for Updates
REFLECTION: A Clinical Practice Learning Program for Galleri®
NCT05205967
Recruiting
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
Gender:
All
Ages:
22 years and above
Trial Updated:
05/17/2024
Locations: Providence, St. Jude, Fullerton, California
Conditions: Early Detection of Cancer, Cancer
Register for Updates
Eyelid Androgen Treatment in Dry Eye
NCT06154200
Recruiting
The purpose of this research study is to evaluate the effectiveness and safety of applying androgen sex hormone (i.e., testosterone) gel on the eyelids in the treatment of dry eye patients. Several studies have demonstrated positive treatment effects in dry eye, but few have applied testosterone gels to the eyelids.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Southern California College of Optometry at Marshall B. Ketchum University, Fullerton, California
Conditions: Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Register for Updates
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Providence Medical Foundation, Fullerton, California
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Providence Medical Foundation - Providence St. Joseph, Fullerton, California
Conditions: Breast Cancer
Register for Updates
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
NCT04780685
Recruiting
This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/07/2022
Locations: Providence Medical Foundation, Fullerton, California
Conditions: Covid19
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Fullerton, California
Conditions: Chronic Lymphocytic Leukemia
Register for Updates